Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Wuxi Biologics Ireland Limited has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 8 distinct art units, showing that each pending matter is associated with a separate examiner and art-unit combination in the available profile.
LEUNG, CHRISTINA Y is the busiest examiner, with 1 pending matter. No examiner accounts for a larger concentration of the current workload, so prosecution planning is driven primarily by individual case review rather than by a dominant examiner relationship.
The complete dispersion across examiners and art units makes docket coordination important. Counsel may benefit from maintaining consistent technical positions while tailoring amendments and interview preparation to each examination context. The data points to a distributed biotechnology prosecution profile.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEUNG, CHRISTINA Y | 1 | 77.7% | +1.5% |
| SIEFKE, SAMUEL P | 1 | 63.0% | +17.8% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 67.6% | +52.2% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19348335 | RAMAN SPECTROSCOPY INTEGRATED PERFUSION CELL CULTURE SYSTEM FOR MONITORING AND AUTO-CONTROLLING PERFUSION CELLCULTURE | LEUNG, CHRISTINA Y | — |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 54d |
| 18702286 | SYSTEMS FOR THE EXTRACTION OF MACROMOLECULES | SIEFKE, SAMUEL P | — |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — |
| 18272548 | POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION | BORGEEST, CHRISTINA M | — |
| 18265338 | AN ANTIBODY AGAINST P-CADHERIN AND USES THEREOF | HOWARD, ZACHARY C | — |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1758 | 1 |
| 1798 | 1 |
| 1675 | 1 |
| 1674 | 1 |
| 1633 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19348335 | RAMAN SPECTROSCOPY INTEGRATED PERFUSION CELL CULTURE SYSTEM FOR MONITORING AND AUTO-CONTROLLING PERFUSION CELLCULTURE | LEUNG, CHRISTINA Y | 3991 | §103§112 | Non-Final OA | — | Pending | Oct 02, 2025 |
| 18702286 | SYSTEMS FOR THE EXTRACTION OF MACROMOLECULES | SIEFKE, SAMUEL P | 1758 | §102 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | 1798 | §102§103 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18272548 | POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION | BORGEEST, CHRISTINA M | 1675 | §112DP | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18265338 | AN ANTIBODY AGAINST P-CADHERIN AND USES THEREOF | HOWARD, ZACHARY C | 1674 | §112Other | Final Rejection | — | Pending | Jun 05, 2023 |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112Other | Final Rejection | 54d | Pending | Jan 10, 2022 |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | GUSTILO, ESTELLA M | 1646 | §112DP | Non-Final OA | — | Pending | Jul 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuxi Biologics Ireland Limited has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Christina Y Leung has the most, with 1 of Wuxi Biologics Ireland Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
